Nifty
Sensex
:
:
23907.15
75867.80
-6.55 (-0.03%)
-141.90 (-0.19%)

Pharmaceuticals & Drugs - Domestic

Rating :
69/99

BSE: 500488 | NSE: ABBOTINDIA

27735.00
27-May-2026
  • Open
  • High
  • Low
  • Previous Close
  •  27800
  •  27825
  •  27455
  •  27610.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  5170
  •  142919980
  •  37000
  •  25150

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 58,880.12
  • 37.94
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 56,625.17
  • 2.37%
  • 12.33

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.99%
  • 0.71%
  • 13.38%
  • FII
  • DII
  • Others
  • 0.27%
  • 8.72%
  • 1.93%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.38
  • 8.26
  • 6.21

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.62
  • 12.99
  • 7.02

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.68
  • 15.41
  • 14.21

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 48.49
  • 48.61
  • 47.40

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.99
  • 15.25
  • 15.49

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 31.06
  • 32.58
  • 31.96

Earnings Forecasts:

(Updated: 23-05-2026)
Description
2024
2025
2026
2027
Adj EPS
738.88
811.63
896.2
955.82
P/E Ratio
37.54
34.17
30.95
29.02
Revenue
6953.54
7527.74
8187.41
9067.2
EBITDA
1895.4
2099.37
2319.14
2506
Net Income
1570.1
1724.77
1904.43
2031.15
ROA
24.14
24.09
25.18
24.9
P/B Ratio
12.87
11.39
10.17
10.21
ROE
34.99
34.14
34.5
37.04
FCFF
1283.31
1924.07
1795.16
1688.59
FCFF Yield
2.28
3.42
3.19
3
Net Debt
-1758.55
-2383
-2688.85
-2543.1
BVPS
2154.36
2436.05
2726.67
2717.17

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated
Description
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Net Sales
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Expenses
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBITDA
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBIDTM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Other Income
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Interest
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Depreciation
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PBT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Tax
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PAT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PATM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
EPS
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Nov 01
Net Sales
-
356.31
Net Sales Growth
-
 
Cost Of Goods Sold
-
182.40
Gross Profit
-
173.91
GP Margin
-
48.81%
Total Expenditure
-
305.87
Power & Fuel Cost
-
2.92
% Of Sales
-
0.82%
Employee Cost
-
21.63
% Of Sales
-
6.07%
Manufacturing Exp.
-
16.42
% Of Sales
-
4.61%
General & Admin Exp.
-
9.79
% Of Sales
-
2.75%
Selling & Distn. Exp.
-
63.11
% Of Sales
-
17.71%
Miscellaneous Exp.
-
9.59
% Of Sales
-
2.69%
EBITDA
-
50.44
EBITDA Margin
-
14.16%
Other Income
-
20.48
Interest
-
0.12
Depreciation
-
4.48
PBT
-
66.33
Tax
-
16.67
Tax Rate
-
25.13%
PAT
-
49.66
PAT before Minority Interest
-
49.66
Minority Interest
-
0.00
PAT Margin
-
13.94%
PAT Growth
-
 
EPS
-
23.42

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

News Update:


  • Abbott India inks pact with Novo Nordisk India to launch Extensior
    27th Feb 2026, 16:00 PM

    Extensior is a second brand of Ozempic, the world’s most prescribed GLP-1 RA molecule

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.